Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Next Previous
Trial Profile

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms INFUS-ON
  • Sponsors US WorldMeds

    • Most Recent Events

    • 08 Aug 2023 Planned End Date changed from 1 Sep 2021 to 1 Dec 2023.
    • 27 Apr 2023 Results assessing long-term safety and efficacy of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in Parkinson's disease (PD) patients treated in United States (US) settings, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 16 Sep 2020 Results evaluating the efficacy of apomorphine infusion in reducing OFF time during the hours of pump use in PD patients presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top